Manfreda F, Palmieri D, Antinolfi P, Rinonapoli G, Caraffa A
1 Department of Orthopedics and Traumatology, University of Perugia, Perugia, Italy.
2 Division of Orthopedics and Trauma Surgery, Santa Maria della Misericordia Hospital, Perugia, Italy.
J Orthop Surg (Hong Kong). 2019 May-Aug;27(2):2309499019842424. doi: 10.1177/2309499019842424.
Patellar tendinopathy is a disease affecting particularly athletes. Platelet-rich plasma (PRP) injections have gained increasing interest for their potential benefits. Anyway, a tendon disease longer than 6 months should be considered as an indication for surgery. The aim of our study was to evaluate the efficacy of PRP in athletes with a severe chronic patellar tendinopathy longer than 6 months when surgery should be chosen.
We enrolled 17 sport practitioners (19 patellar tendons) who did not want to undergo surgery and who are nonresponders to other conservative treatments. We treated them with PRP and calculated the results using the visual analog scale (VAS), the Victorian Institute of Sport Assessment-Patellar (VISA-P) score, and Tegner Activity Scale. Every test has been conducted at T0, T1 (4 months), and T2 (12 months).
We found a poor improvement at T1 and a clinical worsening at T2 through VAS. VISA-P showed a medium improvement both at T1 and T2. Tegner scale did not show improvements.
Our study was not able to remove the doubts about the benefits of PRP in patellar tendinopathy, confirming ambiguous certainties. Further investigations are needed to assess its effectiveness.
髌腱病是一种尤其影响运动员的疾病。富含血小板血浆（PRP）注射因其潜在益处而越来越受到关注。无论如何，病程超过6个月的肌腱疾病应被视为手术指征。我们研究的目的是评估PRP对病程超过6个月、应选择手术治疗的重度慢性髌腱病运动员的疗效。
我们招募了17名不愿接受手术且对其他保守治疗无反应的运动从业者（19条髌腱）。我们用PRP对他们进行治疗，并使用视觉模拟量表（VAS）、维多利亚运动评估髌腱量表（VISA - P）评分和特格纳活动量表计算结果。每项测试均在T0、T1（4个月）和T2（12个月）进行。
通过VAS发现，在T1时改善不佳，在T2时临床症状恶化。VISA - P在T1和T2时均显示中等程度改善。特格纳量表未显示出改善。
我们的研究未能消除对PRP治疗髌腱病益处的疑虑，证实了某些不明确的情况。需要进一步研究来评估其有效性。
